Susceptibility to paromomycin in clinical isolates and reference strains of Leishmania species responsible for tegumentary leishmaniasis in Brazil

Autor(es)

Coser, Elizabeth M. ^[1] ; Ferreira, Bianca A. ^[1] ; Yamashiro-Kanashiro, Edite H. ^{[2, 3]} ; Lindoso, Jose Angelo L. ^{[4, 5]} ; Coelho, Adriano C. ^[1]

Afiliação do(s) autor(es)

^[1] Univ Estadual Campinas UNICAMP, Inst Biol, Dept Biol Anim, Campinas - Brazil

^[2] Univ Sao Paulo, Fac Med, Inst Med Trop Sao Paulo, Lab Soroepidemiol & Imunobiol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Imunol LIM 48, Sao Paulo - Brazil

^[4] Inst Infectol Emilio Ribas, Sao Paulo - Brazil

^[5] Univ Sao Paulo, Fac Med, Dept Molestias Infecciosas & Parasitarias, Lab Protozool, Inst Med Trop Sao Paulo, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: Acta Tropica; v. 215, MAR 2021.
• Citações Web of Science: 1

Resumo

Treatment of tegumentary leishmaniasis in Brazil is limited to pentavalent antimonial, amphotericin B and pentamidine. These drugs, administered parenterally, cause several side effects and have a varied clinical response, depending on the species of Leishmania. Urgent expansion of the therapeutic arsenal against the disease is therefore necessary. Pammomycin is an aminoglycoside antibiotic that has already been approved for the treatment of visceral leishmaniasis in Southeast Asia. Here, we provide an in vitro evaluation of the activity of paromomycin in fifteen clinical isolates from patients with tegumentary leishmaniasis at a reference center for the treatment of the disease. Furthermore, the in vitro susceptibility to this drug in reference strains of Leishmania species that are endemic in Brazil has also been evaluated. Among the clinical isolates, nine were typed as Leishmania (Viannia) braziliensis, five as L. (Leishmania) amazonensis and one as L. (V.) guyanensis. Although never exposed to paromomycin, we found variable susceptibility among these isolates and reference strains in promastigotes and intracellular amastigotes, with the drug being more active in the amastigote form of the parasite. This study provides a preclinical dataset that is useful for the evaluation of pammomycin in the treatment of tegumentary leishmaniasis caused by species that are endemic in Brazil. (AU)

• Processo FAPESP: 16/21171-6 - Paromomicina no tratamento da Leishmaniose Tegumentar: investigação in vitro, in vivo e na identificação de marcadores moleculares associados à suscetibilidade e resistência
• Beneficiário: Adriano Cappellazzo Coelho
• Linha de fomento: Auxílio à Pesquisa - Apoio a Jovens Pesquisadores
• Processo FAPESP: 20/01948-1 - Avaliação da suscetibilidade in vitro a fármacos alternativos em isolados clínicos e de cães de Leishmania spp
• Beneficiário: Bianca Alves Ferreira
• Linha de fomento: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/03299-0 - Avaliação da eficácia da paromomicina no tratamento da leishmaniose tegumentar experimental
• Beneficiário: Elizabeth Magiolo Coser
• Linha de fomento: Bolsas no Brasil - Mestrado